Current Clinical trials
List of trials with a brief description of type of trial and which sites are recruiting.
Click onto TRIAL NAME this will open page to inclusion/exclusion details and contact details.
Click on to phase I, II, III or IV and there will be a brief description for that phase.
MSLT II - A phase III multicenter randomised trial of sentinel lymphadenectomy and node dissection versus sentinel lymphodenectomy alone, in cutaneous melanoma with molecular or histopathological evidence of metastasis in the sentinel node.
Sites recruiting – Sydney Melanoma Unit (North Sydney), Newcastle Melanoma Unit
M10 - 440 - A Phase II Randomized, Double-Blind, Placebo-Controlled Study. Evaluating the Efficacy of ABT-888 in Combination with Temozolomide Versus Temozolomide Alone in Subjects with Metastatic Melanoma
Sites recruiting – Newcastle Melanoma Unit, Sydney Cancer Centre (RPA)
TEAM - Biomarker evaluation of short-term administration of chemotherapeutic or biologic agents in patients with unresectable Stage IIIb, IIIc or IV melanoma amenable to pre- and post-treatment biopsy.
Sites recruiting – Sydney Melanoma Unit (North Sydney), Westmead Hospital
Whole Brain Radiotherapy - Stage IV Melanoma, Intent of treatment: This study aims to improve the treatment of brain metastases for patients with stage IV melanoma by using WBRT to improve disease control, and maintain cognitive performance and quality of life.
Sites recruiting – Sydney Melanoma Unit (RPA), Royal North Shore Hospital, Calvary Mater Newcastle, St Vincents Hospital
Chemosensitivity - A study of the molecular profile of melanoma chemosensitivity and resistance in patients undergoing intravenous limb infusion for metastatic melanoma.
Sites recruiting – Sydney Melanoma Unit (North Sydney)
ECOG-1697 – Phase III randomised adjuvant study of high-dose INF alfa-2b v observation for stage II or III melanoma. The objectives are to compare the effect on the relapsefree, overall, quality-adjusted survival and assess the toxicity. Target is 1420 patients.
Sites recruiting – Westmead Hospital, Newcastle Melanoma Unit
GSK DERMA - A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma with macroscopic lymph node involvement.
Sites recruiting - Sydney Melanoma Unit (RPA), Newcastle Melanoma Unit
EORTC 18071 - A randomized double-blind, Phase III trial of the EORTC Melanoma Group. Adjuvant immunotherapy with anti-CTLA-4 monclonal antibody (ipilimumab) versus placebo after complete rescetion of high-risk Stage III melanoma.
Sites recruiting - Newcastle Melanoma Unit
Topical immunotherapy with diphencyprone for cutaneous metastatic melanoma - Cutaneous recurrent/metastatic disease unsuitable for surgery or radiotherapy.
Sites recruiting - Dermatology Unit (RPA)
